We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
One of the federal investigations into a reverse-payment deal involving generic Plavix found no violations of federal securities laws on the part of Bristol-Myers Squibb (BMS), the company said.
Industry involvement in breast cancer trials may affect study design, focus and results, according to an article published in the online version of the journal Cancer.
As Capitol Hill contemplates proposed legislation to establish approval mechanisms and analytical processes at the FDA to facilitate biogeneric entry, biotech firms are urging federal lawmakers to reject assertions in two highly publicized studies that claim follow-on biologics would save billions in healthcare costs.
The Michigan House of Representatives voted to repeal a state law that prevents residents from suing drug companies — the only law of its kind in the country.
Merck has decided to pull back its lobbying efforts to promote state-mandated vaccinations of adolescent girls with Gardasil, a vaccine to guard against two strains of the human papillomavirus (HPV), a company representative confirmed.
Merck has decided to pull back its lobbying efforts to promote state-mandated vaccinations of adolescent girls with Gardasil, a vaccine to guard against two strains of the human papillomavirus (HPV), a company representative confirmed.
Teva Pharmaceutical reported $460 million in earnings for the fourth quarter of 2006, reflecting a 51 percent increase from the $305 million posted in the same period a year earlier.
The FTC will continue to pursue an anticompetitive case against Barr Laboratories following a federal district court ruling rejecting the generic firm’s motion to dismiss the case, agency sources say.
A pathway for creating and marketing generic biologics could help health plan sponsors and patients save $71 billion over the next 10 years, according to an Express Scripts report.